Interleukin-2, Polyethylene Glycolated

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Chiron Corporation, Rockefeller University

Conditions

HIV Infections

Phase 1

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

CompletedNCT00001036

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 12Updated: 2008-07-30

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

CompletedNCT00000664

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 26Updated: 2008-08-04

Unknown Phase

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

CompletedNCT00002017

Rockefeller UniversityHIV Infections

Updated: 2005-06-24

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals

CompletedNCT00001997

Chiron CorporationHIV Infections

Updated: 2005-06-24